All In Biotech

Drug Trial Radar · NCT03056040

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

202

Actual

Start

May 17, 2017

Primary completion

Feb 21, 2022

Study completion Feb 21, 2022

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 16, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who were clinically stable after having been treated with eculizumab for at least 6 months.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

  • RavulizumabBiological

    All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilograms (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.

  • EculizumabBiological

    All treatments were given as IV infusions. Participants received 900 mg of eculizumab q2w.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change In Lactate Dehydrogenase Levels From Baseline To Day 183Time frame: Baseline, Day 183

Locations

51 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California

  • Research Site

    Los Angeles, California

  • Research Site

    Baltimore, Maryland

  • Research Site

    Detroit, Michigan

  • Research Site

    The Bronx, New York

  • Research Site

    Canberra, Australia

  • Research Site

    Kogarah, Australia

  • Research Site

    Liverpool, Australia

  • Research Site

    Melbourne, Australia

  • Research Site

    Woolloongabba, Australia

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Amiens, France

  • Research Site

    La Tronche, France

  • Research Site

    Marseille, France

  • Research Site

    Nice, France

  • Research Site

    Paris, France

  • Research Site

    Pierre-Bénite, France

  • Research Site

    Saint-Priest-en-Jarez, France

  • Research Site

    Strasbourg, France

  • Research Site

    Aachen, Germany

  • Research Site

    Essen, Germany

  • Research Site

    Ulm, Germany

  • Research Site

    Florence, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Naples, Italy

  • Research Site

    Torino, Italy

  • Research Site

    Vicenza, Italy

  • Research Site

    Fukushima, Japan

  • Research Site

    Kanazawa, Japan

  • Research Site

    Shinagawa-ku, Japan

  • Research Site

    Suita-shi, Japan

  • Research Site

    Suwa-shi, Japan

  • Research Site

    Maastricht, Netherlands

  • Research Site

    Nijmegen, Netherlands

  • Research Site

    Bucheon-si, South Korea

  • Research Site

    Daegu, South Korea

  • Research Site

    Daejeon, South Korea

  • Research Site

    Incheon, South Korea

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.